Celgene Corp
NASDAQ:CELG
$72.01
-$0.86
(-1.17%)
Quote as of 3:59 PM EST on 02/09/12
|
$72.01
-$0.86
(-1.17%)
|
|
| Today's Open | $73.15 |
|---|---|
| Previous Close | $72.86 |
| Daily Range | $71.92 - $73.19 |
| 52-Week Range | $50.11 - $75.11 |
| Market Cap | $31.97B |
| P/E Ratio | 19.22 |
| Dividend (Yield) | $0.00 (0.0%) |
| Volume | 3,478,290 |
| Average Daily Volume | 3,324,755 |
| Current FY EPS | $4.41 |
CELG Information
| Description |
|---|
| A biopharmaceutical company primarily engaged in the discovery, development and commercialization of innovative therapies designed to treat cancer and immune-inflammatory related diseases. |
| Sector |
| Healthcare |
| Industry |
| Biotechnology |
News & Commentary
Blood Disease Drug Dacogen Gets Thumbs Down for Cancer Use
Has Amgen Become the Perfect Stock?
Which Big Biotech Is the Best Bet?
Celgene Meets on the Top Line, Misses Where It Counts
2 Biotech Acquisitions in 1 Day! Let's Throw a Party
Celgene To Buy Avila For $350 Million Cash; 4Q Net Rises 96%
The Zacks Analyst Blog Highlights: Celgene, Advanced Micro Devices, Seagate, Western Digital and Int
Celgene Misses Narrowly in 4Q - Analyst Blog
Amgen, Celgene, Roche Deals Signal M&A Frenzy for Drug Companies
UPDATE: Celgene To Buy Avila For Up To $925 Million; 4Q Net Up 96%
